Filing Details
- Accession Number:
- 0001725160-21-000050
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-03 16:35:17
- Reporting Period:
- 2021-03-01
- Accepted Time:
- 2021-03-03 16:35:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1725160 | Zentalis Pharmaceuticals Inc. | ZNTL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1807359 | Epperly Melissa B, | C/O Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue, Suite 2201 New York NY 10018 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-03-01 | 3,083 | $41.67 | 283,430 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
Billionaire Hedge Funds
